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Purpose. To evaluate daily spectral-domain optical coherence tomography (SD-OCT) changes in naive-treatment patients with
diagnosis of exudative age-relatedmacular degeneration (AMD) treated with intravitreous bevacizumab (1.25mg), during a 30-day
follow-up period.Methods. In prospective, interventional study, SD-OCTwas performed daily for 30 days after the first intravitreal
injection. The baseline, initial-decrease, minimal, and final central retinal thicknesses (CRTs) were assessed. Results. Nine eyes of
nine patients with neovascular AMD were enrolled. The mean baseline CRT was 625.3 ± 182.5 𝜇m, and the mean final CRT was
383.4 ± 163.0 𝜇m (mean difference, 206.1 ± 167.6 𝜇m), a difference that reached significance (𝑃 = 0.006). After the first injection,
the initial decrease in the CRT was seen as an average of one day after injection (mean CRT, 503.6 ± 189.10 𝜇m; 𝑃 = 0.0431). The
speed of the reduction in the CRT tended to decrease by day 17. The mean CRT was 336.5 ± 105.44 𝜇m and the mean minimal
CRT on day 30 was 320.75 ± 96.38 𝜇m. Conclusion.The CRT decreased early after the first injection. We observed a tendency for
reductions in the speed with which the CRT decreased by day 17 after the first injection, which may affect retreatment regime.
1. Introduction
Age-related macular degeneration (AMD) is the leading
cause of irreversible blindness in patients older than 50 years
inWestern countries [1–3]. Vascular endotheliumgrowth fac-
tor (VEGF) plays an important role inwetAMD[4]. As a con-
sequence,many ophthalmologistsworldwide have been using
anti-VEGF drugs such as bevacizumab (Avastin, Genentech,
Inc., South San Francisco, CA), ranibizumab (Lucentis,
Genentech, Inc.), and aflibercept (Eylea, Regeneron Pharma-
ceuticals, Tarrytown, NY) [5] to attenuate the progression of
this disease and in some cases restore vision [5–8].
Bevacizumab is a humanized IgG1 monoclonal antibody
that binds and inhibits all isoforms of VEGF-A. The US
Food & Drug Administration (FDA) approved the drug to
treat metastatic colorectal cancer. Michels et al. proposed use
of bevacizumab as an intravitreous treatment for exudative
AMD in 2005, when they noticed that the visual acuity (VA)
improved in patients treated with systemic bevacizumab for
metastatic colorectal cancer [9]. Because bevacizumab is not
FDA approved for intravitreous use, it is classified as off-label
for this application. However, it is a low-cost alternative to
ranibizumab or aflibercept.
The monthly intravitreal dose of bevacizumab was deter-
mined based on pharmacokinetics studies [10, 11]. However,
to our knowledge, no clinical correlation has confirmed the
best time for retreatment. Spectral-domain optical coherency
tomography (SD-OCT) provides high-resolution anatomic
images of retinal changes that can indicate the optimal timing
of a new injection and facilitate a better understanding of the
unknown pharmacokinetics of anti-VEGF drugs. To better
understand the retinal changes, our research group per-
formed daily SD-OCT examinations for 30 days in treatment-
naive patients with active exudative AMD.
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Table 1: Patient data.
Patient Gender Age(years)
Baseline
VA
Baseline
CRT
First day of
CRT
reduction
Day of
minimal CRT
Day of
maximal
CRT
Minimal
CRT
Maximum
CRT
1 M 82 20/400 767 2 30 2 355 845
2 W 80 20/100 378 2 17 1 249 400
3 M 74 20/80 364 1 30 1 208 364
4 M 69 20/60 453 1 16 1 361 453
5 W 83 20/200 755 1 30 1 331 755
6 W 65 20/400 815 1 15 1 729 787
7 W 66 20/150 595 1 14 1 303 453
8 W 72 20/200 784 1 29 1 397 707
9 W 79 20/400 717 1 16 1 577 697
M: man; W: woman; VA: visual acuity; CRT: central retinal thickness.
2. Methods
This was a prospective, interventional study conducted at
the Department of Ophthalmology and approved by Federal
University of Sao Paulo (UNIFESP), School of Medicine
Institutional Review Board (IRB [#0345/10]). The research
adhered to the tenets of the Declaration of Helsinki. Written
informed consent was obtained before OCT examination in
accordance with the UNIFESP IRB.
Nine patients were enrolled; the eligibility criteria were
an age of 50 years or more, presence in a study eye of pre-
viously untreated active choroidal neovascularization (CNV)
due to AMD, central macular thickness over 250 𝜇m, VA
between 20/25 and 20/400 using the Early TreatmentDiabetic
Retinopathy Study (ETDRS) chart, and unremarkable past
ocular history. All patients underwent a baseline complete
ophthalmologic examination, SD-OCT using the Spectralis
OCT (Heidelberg Engineering, Heidelberg, Germany), and
fluorescein angiography (FA) to warrant a correct diagnosis.
After the baseline evaluation (day 0), bevacizumab
(1.25mg/0.05mL)was injected into the vitreous cavity of each
patient at the same visit. The patients were instructed to use
topical antibiotics (moxifloxacin 0.3%) four times daily for 5
days. Commercially acquired bevacizumab was repackaged
in glass vials in an aseptic filling facility.
Daily SD-OCT evaluations were performed for 30 con-
secutive days after the injection. After pupillary dilation, a
30-degree central macular line B-scan was performed with
the automatic real-time follow-up function of eye tracking in
the Spectralis OCT unit. Automated inner and outer retinal
segmentation were used to assess central retinal thickness
(CRT), and misidentifications of segmentation boundaries
were confirmed and manually corrected to avoid segmen-
tation errors that could have influenced macular thickness
measurements. The baseline, initial decrease, and minimal
and final CRTs were assessed. Patients whomissed 10% of the
examinations were excluded from the study.
2.1. Statistical Analysis. Data were collected daily from all
patients after the first intravitreal injection and expressed
as the mean (±standard deviation). The Wilcoxon signed-
rank test was performed to compare the preinjection and
postinjection retinal thicknesses. Stata version 11 (StataCorp,
College Station, Texas) was used for all analyses. 𝑃 values
< 0.05 were considered statistically significant.
3. Results
Nine eyes from nine patients (mean age of 74.4 years; 6
women, 3 men) with na¨ıve-treatment active neovascular
AMD were enrolled. All patients had active CNV confirmed
by FA. Four patients were diagnosed as predominantly classic
and five as occult according to the FA classification.Themean
number of OCT examinations was 27.8 ± 0.78. No ocular or
systemic side effects developed during the follow-up period.
Themean baseline CRT was 625.3±182.5 𝜇m; the mean final
CRTwas 383.4±163.0 𝜇m(meandifference, 206.1±167.6 𝜇m)
between the two measurements (𝑃 = 0.006). Table 1 shows
the data from all patients.
After the anti-VEGF injection, we noticed a decrease in
the CRT (mean, 503.6 ± 189.10 𝜇m; 𝑃 = 0.0431) starting on
average on day 1 (Figure 1). On day 17, the mean CRT was
336.5 ± 105.44 𝜇m, and the mean minimal CRT on day 30
was 320.75 ± 96.38 𝜇m. Figure 2 shows the daily progression
of the CRT in each patient. Figure 3 shows the 30-day OCT
images from one patient.
On the predominantly classic classification, the mean
CRT difference between the baseline and day 30 was
161.25 ± 171.10 𝜇m and for the occult classification was
242 ± 174.89 𝜇m (𝑃 = 0.4624). The mean CRT difference
between the baseline and day 17 for the predominantly classic
classification was 154 ± 119.16 𝜇m, and for the occult group
this difference was 244.80 ± 140.68 𝜇m (𝑃 = 0.3272).
4. Discussion
Intravitreal injections of VEGF inhibitors have become the
preferred treatment for a wide range of exudative eye diseases
because of their antiangiogenic and antipermeability effects
[12]. Since the initiation of intravitreous anti-VEGF therapy,
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Figure 1: Cross-sectional one-line optical coherence tomography (OCT) B-scans of patient 8. (a) Pretreatment baseline visit. OCT B-scan
shows a type 2 neovascular membrane presented as a hyperreflective image above the retinal pigment epithelium, associated with subretinal
fluid and intraretinal cysts. (b) OCT B-scan follow-up with eye tracking after the first day after bevacizumab injection with decrease of
subretinal fluid and intraretinal cysts. (c) Two-day follow-up shows an important decrease of the intraretinal cyst (yellow arrows).
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Figure 2: Daily central macular thickness measurements. The
different colors represent each patient.
ophthalmologists worldwide have created new hope for
good treatment outcomes in patients with wet AMD. The
improvements in VA and the decreases in subretinal fluid
(SRF) and CRT were marked with this class of drug.
Although studies have confirmed that anti-VEGF drugs
decrease the CRT and improve the VA in patients with
AMD within a 4-week period, few pharmacokinetic studies
have been conducted in humans to study intravitreous beva-
cizumab and ranibizumab [13–15]. Pharmacokinetic studies
that have been performed have shown a rapid decrease
in the circulating VEGF levels in the vitreous cavity, and
even though the VEGF levels in humans remain undetected
for 6 to 7 weeks after the anti-VEGF injection [13–15], the
clinical changes are not in parallel with this result, since
most increases in the CRT and SRF are observed during
week 4. However, it is unknown if worsening of the clinical
presentation occurs at that time or before, since in most
practices the OCT evaluations of those patients have been
performed only at the 4-week time point. The intravitreal
half-lives of ranibizumab and bevacizumab in humans are
estimated to be 7.9 and 9.73 days, respectively [16]. During
the follow-up visits of patient 4, it was possible to identify
subretinal fluid recurrence on the 18th day. Even though the
final CRT from this patient was thinner than the baseline
visit, there was a slow increase of the SRF from day 18
until day 30 (Figures 2 and 3). Also, the lack of incom-
plete response to anti-VEGF, in some patients (up to 10%)
[17, 18], could be related to upregulation of proinflamma-
tory factors, secondary to VEGF downregulation. In these
incomplete responders, steroidal anti-inflammatory drugs
(triamcinolone and dexamethasone) are well known for their
positive effects on AMD [19–21].
The monthly injection was proposed based on a phase
II study and animal models that addressed the safety and
efficiency of that regimen [10, 11]. In a recent mathematical-
model pharmacokinetic study, Stewart et al. showed that
biweekly injections of anti-VEGF drugs presented higher
trough levels and consecutive increases in the VEGF binding
activity [22]. However, no clinical correlation has confirmed
the optimal dosing. As a consequence, the precise interval of
each injection is unknown.
More recently, there has been increasing concern about
the development or enlargement of atrophic areas of the
retina, glomerular disease, death, and arteriothrombotic
events associated with repeated intraocular anti-VEGF [23,
24].The 2-year results of the Comparison of AMDTreatment
Trials (CATT) show that development of geographic atrophy
(GA) was higher in the anti-VEGF monthly dosing group
compared to the as-needed group [24]. On another study
that analyzed the second-year results of the CATT, Sharma
et al. showed that many features were associated with the
largest decreases in VA at week 104, such as intraretinal
fluid, extremely thin or thick CRT, an increase of CNV
area, increasing foveal scar, and foveal GA. However, only
intraretinal fluid was independently associated with worse
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Figure 3: Daily cross-sectional one-line optical coherence tomography (OCT) B-scans over a 30-day period of patient 4. Immediately
posttreatment decrease of central retinal thickness with rebound increase of subretinal fluid during follow-up, starting at day 18. On day
30, it is possible to identify the recurrent SRF (yellow arrowhead).
VA at the second year of follow-up [25]. Grunwald and
associates analyzed the growth of GA in the CATT and found
no significant difference between subjects treated monthly
and subjects treated as-needed [26]. In addition, since the
CATT did not include a placebo treatment arm, we cannot
determine whether anti-VEGF therapy has an effect on GA
growth that is different from the natural history of GA
developing in eyeswith exudativeAMD.Using gene-profiling
assays to induce RPE-specific VEGF inactivation in mice,
Kurihara et al. demonstrated that the decrease of VEGF
affects the expression of multiple angiogenesis-related genes
in isolated RPE-choroid preparations, leading to choriocap-
illaris loss and secondary cone photoreceptors dysfunction
[27]. In another study, Saint-Geniez and colleagues showed
that VEGF inhibition in mice leads to RPE dysfunction,
accumulation of drusen-like basal deposits, and loss of
Journal of Ophthalmology 5
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Figure 4: Mean CRT measurements (microns) during the 30-day
follow-up.
barrier proprieties. Those findings are also often found in
patients with AMD [28]. These changes preceded the devel-
opment of GA [29]. However, there are no studies in humans
showing a correlation between loss of retinal function and
VEGF inhibitors. Thus, even though the risk of development
or enlargement of GA may exist, it should be taken into
consideration that undertreatment of wet AMD may have a
higher impact on the VA.
In the current study, we identified an immediate initial
decrease in the CRT and the amount of intraretinal fluid and
SRF. The initial decreases in the CRT and SRF in the current
study were consistent with previous pharmacokinetics stud-
ies and began the first day after the intravitreal injection of
anti-VEGFmedication. Hence, while the initial changes were
similar to those reported previously, we observed a tendency
for reductions in the speed with which the CRT decreased
after day 17, which differed from the 6- to 7-week period of
VEGF intravitreal inhibition in previous pharmacokinetics
studies (Figure 4). However, even though our study described
changes in CRT, it is important to highlight the fact that the
functional improvements, such as an increase in VA, should
be evaluated in combinationwithOCT for clinical evaluation.
In conclusion, since the current study showed different
behavior of the intravitreal injections compared to studies
that support current treatment regimen, we strongly support
new studies of anti-VEGF intravitreal injections with a 2-
week regimen compared to the standard 4-week regimen.
Abbreviations
AMD: Age-related macular degeneration
VEGF: Vascular endothelium growth factor
FDA: Food & Drug Administration
VA: Visual acuity
SD-OCT: Spectral-domain optical coherency tomography
IRB: Institutional Review Board
CNV: Choroidal neovascularization
ETDRS: Early Treatment Diabetic Retinopathy Study
FA: Fluorescein angiography
CRT: Central retinal thickness
SRF: Subretinal fluid.
Competing Interests
The authors have no financial interests to disclose.
References
[1] R. Klein, C.-F. Chou, B. E. K. Klein, X. Zhang, S. M. Meuer, and
J. B. Saaddine, “Prevalence of age-related macular degeneration
in the US population,” Archives of Ophthalmology, vol. 129, no.
1, pp. 75–80, 2011.
[2] N. Congdon, B. O’Colmain, C. C. Klaver et al., “Eye Dis-
eases Prevalence Research G: causes and prevalence of visual
impairment among adults in the United States,” Archives of
Ophthalmology, vol. 122, pp. 477–485, 2004.
[3] R. Klein, Q. Wang, B. E. K. Klein, S. E. Moss, and S. M.
Meuer, “The relationship of age-related maculopathy, cataract,
and glaucoma to visual acuity,” Investigative Ophthalmology and
Visual Science, vol. 36, no. 1, pp. 182–191, 1995.
[4] J.W.Miller, J. Le Couter, E. C. Strauss, andN. Ferrara, “Vascular
endothelial growth factor a in intraocular vascular disease,”
Ophthalmology, vol. 120, no. 1, pp. 106–114, 2013.
[5] P. Mitchell, “A systematic review of the efficacy and safety
outcomes of anti-VEGF agents used for treating neovascular
age-related macular degeneration: comparison of ranibizumab
and bevacizumab,” Current Medical Research and Opinion, vol.
27, no. 7, pp. 1465–1475, 2011.
[6] A. F. Cruess, A. Berger, K. Colleaux et al., “Canadian expert con-
sensus: optimal treatment of neovascular age-related macular
degeneration,” Canadian Journal of Ophthalmology, vol. 47, no.
3, pp. 227–235, 2012.
[7] D. Veritti, V. Sarao, and P. Lanzetta, “Neovascular age-related
macular degeneration,” Ophthalmologica, vol. 227, supplement
1, pp. 11–20, 2012.
[8] D. S. Dhoot and P. K. Kaiser, “Ranibizumab for age-related
macular degeneration,” Expert Opinion on Biological Therapy,
vol. 12, no. 3, pp. 371–383, 2012.
[9] S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus, and
A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy
for neovascular age-related macular degeneration: twelve-week
results of an uncontrolled open-label clinical study,” Ophthal-
mology, vol. 112, no. 6, pp. 1035–1047, 2005.
[10] P. J. Rosenfeld, S. D. Schwartz, M. S. Blumenkranz et al., “Max-
imum tolerated dose of a humanized anti-vascular endothelial
growth factor antibody fragment for treating neovascular age-
related macular degeneration,” Ophthalmology, vol. 112, no. 6,
pp. 1048–1053, 2005.
[11] J. S. Heier, A. N. Antoszyk, P. R. Pavan et al., “Ranibizumab for
treatment of neovascular age-related macular degeneration. A
Phase I/II Multicenter, Controlled, Multidose study,” Ophthal-
mology, vol. 113, no. 4, pp. 642–642.e4, 2006.
[12] T. A. Ciulla and P. J. Rosenfeld, “Anti-vascular endothelial
growth factor therapy for neovascular ocular diseases other
than age-related macular degeneration,” Current Opinion in
Ophthalmology, vol. 20, no. 3, pp. 166–174, 2009.
[13] Q. Zhu, F. Ziemssen, S. Henke-Fahle et al., “Vitreous levels
of bevacizumab and vascular endothelial growth factor-A in
patients with choroidal neovascularization,” Ophthalmology,
vol. 115, no. 10, pp. 1750–1755.e1, 2008.
[14] C. H. Meyer, T. U. Krohne, and F. G. Holz, “Intraocular
pharmacokinetics after a single intravitreal injection of 1.5mg
versus 3.0mg of bevacizumab in humans,” Retina, vol. 31, no. 9,
pp. 1877–1884, 2011.
6 Journal of Ophthalmology
[15] T. U. Krohne, N. Eter, F. G. Holz, and C. H. Meyer, “Intraocular
pharmacokinetics of bevacizumab after a single intravitreal
injection in humans,” American Journal of Ophthalmology, vol.
146, no. 4, pp. 508–512, 2008.
[16] L. A. Hutton-Smith, E. A. Gaffney, H. M. Byrne, P. K. Maini, D.
Schwab, and N. A. Mazer, “A mechanistic model of the intravit-
real pharmacokinetics of large molecules and the pharmacody-
namic suppression of ocular vascular endothelialgrowth factor
levels by ranibizumab in patients with neovascular age-related
macular degeneration,”Molecular Pharmaceutics, 2016.
[17] P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab
for neovascular age-related macular degeneration,” The New
England Journal ofMedicine, vol. 355, no. 14, pp. 1419–1431, 2006.
[18] D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and
T. Ianchulev, “Ranibizumab versus verteporfin photodynamic
therapy for neovascular age-relatedmacular degeneration: two-
year results of the ANCHOR study,”Ophthalmology, vol. 116, no.
1, pp. 57–65.e5, 2009.
[19] A. J. Augustin, S. Puls, and I. Offermann, “Triple therapy for
choroidal neovascularization due to age-relatedmacular degen-
eration: verteporfin PDT, bevacizumab, and dexamethasone,”
Retina, vol. 27, no. 2, pp. 133–140, 2007.
[20] L. Gopal and T. Sharma, “Use of intravitreal injection of tri-
amcinolone acetonide in the treatment of age-related macular
degeneration,” Indian Journal of Ophthalmology, vol. 55, no. 6,
pp. 431–435, 2007.
[21] R. F. Spaide, J. Sorenson, and L. Maranan, “Combined photody-
namic therapy and intravitreal triamcinolone for nonsubfoveal
choroidal neovascularization,” Retina, vol. 25, no. 6, pp. 685–
690, 2005.
[22] M. W. Stewart, P. J. Rosenfeld, F. M. Penha et al., “Pharma-
cokinetic rationale for dosing every 2 weeks versus 4 weeks
with intravitreal ranibizumab, bevacizumab, and aflibercept
(vascular endothelial growth factor Trap-eye),” Retina, vol. 32,
no. 3, pp. 434–457, 2012.
[23] M. B. Stokes, M. C. Erazo, and V. D. D’Agati, “Glomerular
disease related to anti-VEGF therapy,”Kidney International, vol.
74, no. 11, pp. 1487–1491, 2008.
[24] D. F. Martin, M. G. Maguire, S. L. Fine et al., “Ranibizumab and
bevacizumab for treatment of neovascular age-related macular
degeneration: two-year results,” Ophthalmology, vol. 119, no. 7,
pp. 1388–1398, 2012.
[25] S. Sharma, C. A. Toth, E. Daniel et al., “Macular morphology
and visual acuity in the second year of the comparison of age-
related macular degeneration treatments trials,” Ophthalmol-
ogy, vol. 123, no. 4, pp. 865–875, 2016.
[26] J. E. Grunwald, M. Pistilli, G.-S. Ying, M. G. Maguire, E.
Daniel, and D. F. Martin, “Growth of geographic atrophy in
the comparison of age-relatedmacular degeneration treatments
trials,” Ophthalmology, vol. 122, no. 4, pp. 809–816, 2015.
[27] T. Kurihara, P. D. Westenskow, S. Bravo, E. Aguilar, and M.
Friedlander, “Targeted deletion of Vegfa in adult mice induces
vision loss,”The Journal of Clinical Investigation, vol. 122, no. 11,
pp. 4213–4217, 2012.
[28] M. Saint-Geniez, T. Kurihara, E. Sekiyama, A. E. Maldonado,
and P. A. D’Amore, “An essential role for RPE-derived soluble
VEGF in themaintenance of the choriocapillaris,”Proceedings of
the National Academy of Sciences of the United States of America,
vol. 106, no. 44, pp. 18751–18756, 2009.
[29] J. Ambati, B. K. Ambati, S. H. Yoo, S. Ianchulev, and A. P.
Adamis, “Age-related macular degeneration: etiology, patho-
genesis, and therapeutic strategies,” Survey of Ophthalmology,
vol. 48, no. 3, pp. 257–293, 2003.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
